Particularly, amplification or mutations of PIK3CA (encoding the catalytic subunit of PI3K P110α), loss of PTEN, and deregulation of AKT are well-known mechanisms that activate this pathway in approximately 70% of ovarian cancers [11–15]. Here, PIK3CA is linked to ovarian cancer.